Therapeutic potential of Relaxin-2 in Heart Failure with preserved Ejection Fraction (HFpEF)
Joshua B. Palma, Beth A. Gabris-Weber, Brenda McMahon, Anthony J. Mauro, Cynthia St. Hilaire, Rolando A. Cuevas, Thomas Bernd Dschietzig, Guillermo Romero, Guy Salama
This study investigates the therapeutic effects of synthetic Relaxin-2 in HFpEF, showing it reverses diastolic dysfunction and reduces arrhythmia vulnerability in ZSF1 rats.
bioRxiv · May 18, 2026 · PreprintPhysiology